Biological Activity
Potent and selective mTOR inhibitor (IC50 = 2.1 nM). Displays 800-fold cellular selectivity for mTOR over PI3K (cellular EC50 values are 0.25 and 200 nM for mTOR and PI3K respectively). Activates autophagy. Orally available.
Licensing Information
Sold under license from Whitehead Institute for Biomedical Research.
Compound Libraries
Torin 2 is also offered as part of the Tocriscreen Plus and Tocriscreen Kinase Inhibitor Toolbox II. Find out more about compound libraries available from Tocris.
Technical Data
| M. Wt | 432.4 |
| Formula | C24H15F3N4O |
| Storage | Store at +4°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 1223001-51-1 |
| PubChem ID | 51358113 |
| InChI Key | GUXXEUUYCAYESJ-UHFFFAOYSA-N |
| Smiles | O=C(C=C3)N(C5=CC=CC(C(F)(F)F)=C5)C2=C3C=NC1=CC=C(C4=CC=C(N)N=C4)C=C12 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 8.65 | 20 |
Preparing Stock Solutions
The following data is based on the product molecular weight 432.4. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.31 mL | 11.56 mL | 23.13 mL |
| 5 mM | 0.46 mL | 2.31 mL | 4.63 mL |
| 10 mM | 0.23 mL | 1.16 mL | 2.31 mL |
| 50 mM | 0.05 mL | 0.23 mL | 0.46 mL |
Molarity Calculator
Reconstitution Calculator
Dilution Calculator
Product Datasheets
References
References are publications that support the products' biological activity.
Liu et al (2011) Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J.Med.Chem. 54 1473 PMID: 21322566
Simioni et al (2014) Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget 30 10034 PMID: 25296981
Galluzzi et al (2017) Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat.Rev.Drug.Discov. PMID: 28529316
Keywords: Torin 2, supplier, Torin2, mtor, mammalian, target, rapamycin, selective, inhibitors, inhibits, mTOR, Autophagy, mTOR, Tocris Bioscience
